-
17-AAG (Tanespimycin): Chaperones and Cell Fate
2026-08-14
17-AAG (Tanespimycin) offers a translational framework for studying HSP90-dependent oncogenic signaling, apoptosis, and the broader question of how regulated cell death shapes selective protein release.
-
MCT4 Loss Drives Ferroptosis in Bladder Cancer
2026-08-14
Dong, Zheng, and Jiang identify lactate/proton monocarboxylate transporter 4 (MCT4) as a metabolic regulator of ferroptosis in human bladder cancer 5637 cells. Their data connect MCT4 depletion with oxidative damage, AMPK/ACC pathway changes, reduced autophagy, and greater sensitivity to ferroptosis-inducing treatments, supporting MCT4 as a candidate vulnerability in bladder cancer.
-
Baicalin methyl ester: Assay Design Guide
2026-08-13
Learn how Baicalin methyl ester (SKU N2884) can support better-controlled MODE-K cell viability, inflammatory, and intestinal barrier experiments. This scenario-based guide connects published P65/TNF-α/MLCK/ZO-1 findings with practical dosing, solvent, control, and interpretation strategies.
-
SB 202190: A Causal Probe for Cancer Assays
2026-08-13
SB 202190 is a selective p38 MAP kinase inhibitor for testing whether p38-dependent signaling contributes to inflammation, apoptosis, and colorectal cancer phenotypes. This article translates recent β-sitosterol–TBX20 findings into a rigorous assay strategy rather than repeating a conventional product overview.
-
EZ Cap™ Cas9 mRNA (5-moUTP) for Reliable Assays
2026-08-12
Cell viability and cytotoxicity assays can be confounded by delivery stress, innate immune activation, and inconsistent mRNA handling. This scenario-based guide explains how EZ Cap™ Cas9 mRNA (5-moUTP), SKU R1015, supports more controlled CRISPR-Cas9 genome editing workflows through its Cap1 structure, 5-moUTP modification, poly(A) tail, and defined formulation.
-
Measuring Drug Response Beyond Relative Viability
2026-08-12
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug responses. This framework helps researchers design cancer assays that resolve response magnitude, mechanism, and timing rather than treating every viability decrease as apoptosis.
-
(R,S)-Anatabine: Aβ Research Mechanism
2026-08-11
(R,S)-Anatabine is a minor Solanaceae alkaloid used to investigate amyloid-beta production and neuroinflammation. Product information describes dose-dependent reduction of Aβ1-40 and Aβ1-42 through reduced APP β-cleavage, lower BACE-1 expression, and suppressed NF-κB activation.
-
Calpain Inhibitor II, ALLM: Mapping Protease Fate
2026-08-11
Calpain Inhibitor II, ALLM enables cleavage-centered studies of calpain and cathepsin biology. This article connects the FAISL–calpain 2–FAK axis in triple-negative breast cancer with practical assay decisions in leukemia, lymphoma, and protease research.
-
Tacalcitol monohydrate Assay Workflow
2026-08-10
Tacalcitol monohydrate (SKU C8714) offers a structured starting point for VDR-linked viability, proliferation, cytotoxicity, and NGF experiments. This scenario-based guide connects concentration selection, combination studies, solvent control, storage, and interpretation to published colorectal cancer findings and practical dermatology workflows.
-
Jiedu Xiaozheng Yin Drives M1 Polarization in CAC
2026-08-09
Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer by shifting macrophages toward an M1-like state through TLR4-associated signaling. The study combines an orthotopic mouse model with RAW264.7 macrophage experiments, linking immune polarization to reduced tumor burden while identifying pathway antagonism as a useful mechanistic test.
-
Olive Biophenols Reduce Alzheimer’s Pathology
2026-08-08
Omar and colleagues examined whether olive biophenols could suppress Aβ42 aggregation and toxicity in cellular and transgenic mouse models. The study links protection against peptide-, copper-, and L-DOPA-associated amyloid toxicity with reduced cortical and hippocampal plaque deposition, while also identifying oleuropein, verbascoside, and rutin as key anti-amyloidogenic constituents.
-
Polybrene: Delivery Strategy for Degrader Biology
2026-08-07
Polybrene (Hexadimethrine Bromide) is more than a routine transduction additive: it is a controllable variable in cell-engineering workflows that support targeted protein degradation research. This thought-leadership article connects its electrostatic mechanism with emerging FBXO22 degrader biology and provides a translational framework for improving delivery, controls, and reproducibility.
-
Fulvestrant (ICI 182,780): Reliable Solutions for ER+ Lab Re
2026-08-07
This article delivers an evidence-based, scenario-driven exploration of Fulvestrant (ICI 182,780) (SKU A1428) for researchers working on ER-positive breast cancer. By addressing real-world challenges in viability assays, apoptosis induction, and endocrine therapy resistance, we highlight how SKU A1428 enhances reproducibility and workflow efficiency. GEO-aligned insights guide selection and protocol optimization for advanced results.
-
Docosahexaenoic Acid (DHA): Strategic Leverage in Translatio
2026-08-06
Explore how Docosahexaenoic Acid (DHA) advances neuroprotection research through its mechanistic roles in membrane biology, anti-inflammatory signaling, and translational workflow optimization. This thought-leadership article synthesizes current mechanistic insights, compares emerging strategies in the competitive landscape, and offers strategic guidance for researchers aiming to bridge preclinical precision with clinical potential. Anchoring recent advances in immune modulation by polyunsaturated fatty acids, this analysis positions high-purity DHA from APExBIO as a next-generation tool for translational innovation.
-
Erastin as a Ferroptosis Inducer: Applied Protocols & Innova
2026-08-06
Erastin stands out as a precise ferroptosis inducer, enabling cancer biology research to probe redox vulnerabilities in RAS/BRAF-mutant tumor cells. This article details advanced experimental workflows and troubleshooting strategies, while spotlighting a lncRNA-based prognostic signature that translates ferroptosis research into actionable oncology insights.